North America Point of Care Diagnostics Market Outlook, 2031
The North America Point of Care Diagnostics Market is segmented into By Product (Glucose Monitoring Kits, Infectious Diseases Testing Kits, Pregnancy And Fertility Testing Kits, Hematology Testing Kits, Cardiometabolic Monitoring Kits, Urinalysis Testing Kits, Cholesterol Test Strips, Other Products); By Technology/Platform (Lateral Flow Assays, Molecular Diagnostics (PCR/INAAT), Microfluidics & Immunoassays, Dipsticks & Test Strips); By End-User (Hospitals & Critical Care Centers, Clinical & Diagnostic Laboratories, Home Care & Self-Testing); By Mode Of Purchase (Prescription Based Products, OTC Products); By Sample (Blood, Urine, Nasal and Oropharyngeal Swabs).
- Bonafide Research
- 23-09-2026
- Pages : 94
- Figures : 6
- Tables : 19
- Region : North America
- Category : Lifescience & Healthcare
- Medical Devices
- Schedule a Call
-
Sikandar Kesari — Research Analyst
The North America Point of Care Diagnostics Market was valued at more than 18.56 Billion in 2025, driven by the growing demand for rapid and convenient testing.
- Historical Period2020-2024
- Base Year2025
- Forecast Period2026-2031
- Market Size (2025) USD 18.56 Billion
- Largest MarketUnited States
- Fastest Market United States
- Format
Featured Companies
- 1. Abbott Laboratories
- 2. Danaher
- 3. F. Hoffmann-La Roche AG,
- 4. Siemens Healthineers
- 5. OraSure Technologies
- 6. Thermo Fisher Scientific Inc
- More...
Point of Care Diagnostics Market Analysis
The North American Point-of-Care (POC) Diagnostics market represents medical testing conducted near the patient such as in bedside hospital units, urgent care clinics, physician offices, and home-care settings to deliver rapid, actionable clinical results without relying on centralized laboratories. Holding a dominant global share, the market is projected to expand steadily, driven by a growing preference for decentralized healthcare delivery and immediate clinical decision-making. Primary growth drivers include the rising prevalence of chronic conditions like diabetes and infectious diseases, an aging demographic requiring continuous health monitoring, and a strong trend toward home self-testing. Crucial to modern care, POC testing accelerates treatment interventions, reduces turnaround times, lowers total hospitalization costs, and enhances operational efficiency. Major industry stakeholders and key research activities are actively supported by government and private entities such as the National Institutes of Health (NIH), which funds tech advancement through its Point-of-Care Technologies Research Network (POCTRN), alongside trade associations like the American Association for Clinical Chemistry (AACC). Their activities focus on standardizing test accuracy, integrating microfluidics, biosensors, and AI-enabled digital platforms, advocating for favorable reimbursement policies, and validating next-generation diagnostic tools to ensure seamless data integration with electronic health records. Furthermore, strategic mergers and acquisitions among major medical device manufacturers continue to consolidate technology portfolios, driving broader adoption of connected, real-time diagnostic ecosystems across North American healthcare networks. According to the research report, "North America Point of Care Diagnostics Market Outlook, 2031," published by Bonafide Research, the North America Point of Care Diagnostics Market was valued at more than 18.56 Billion in 2025.Major industry leaders including Abbott Laboratories, Roche, Danaher Corporation, Becton Dickinson (BD), Siemens Healthineers, and QuidelOrtho drive market activity through high-impact product developments, such as Abbott securing regulatory clearances for rapid traumatic brain injury blood tests and QuidelOrtho expanding multiplex immunoassay platforms. Significant opportunities lie in expanding microfluidic lab-on-a-chip technologies, AI-guided diagnostic interpretation, and at-home chronic disease monitoring for diabetes, cardiac markers, and infectious conditions. Comprehensive supply chain analysis reveals a highly specialized network spanning raw reagent sourcing, semiconductor and microfluidic component manufacturing, automated assembly, and temperature-controlled cold-chain distribution. To mitigate recent supply chain vulnerabilities and material shortages, major manufacturers are actively nearshoring cartridge manufacturing, securing multi-source polymer agreements, and strengthening distribution channels through partnerships with healthcare distributors and retail pharmacy networks. Additionally, the rapid integration of point-of-care testing into retail pharmacy networks and urgent care chains is drastically expanding community-level patient access across North America. Concurrently, rising regulatory momentum behind over-the-counter (OTC) and multiplex respiratory panels allows consumers to simultaneously screen for Flu, RSV, and COVID-19 at home.
to Download this information in a PDF
What's Inside a Bonafide Research`s industry report?
A Bonafide Research industry report provides in-depth market analysis, trends, competitive insights, and strategic recommendations to help businesses make informed decisions.
Download SampleMarket Dynamics
Market Drivers
• Rising burden of chronic and infectious diseases coupled with an aging demographic: North America faces a massive epidemiological shift driven by a growing geriatric population that requires frequent, long-term health management. Chronic conditions such as type 1 and type 2 diabetes, cardiovascular diseases, kidney disorders, and respiratory illnesses are at all-time highs. Managing these conditions efficiently requires rapid, repeatable diagnostic monitoring such as continuous or point-of-care blood glucose monitoring, HbA1c testing, lipid profiling, and cardiac biomarker assays. By delivering rapid diagnostic feedback, POC devices reduce turnaround times from days to minutes, allowing clinicians to make real-time therapeutic adjustments, prevent acute disease exacerbations, and avoid expensive hospital readmissions.• Decentralization of healthcare delivery and the shift toward patient-centric care: Modern healthcare delivery models in the U.S. and Canada are aggressively shifting clinical encounters away from overburdened acute-care hospitals into outpatient settings, urgent care centers, retail clinics (e.g., CVS MinuteClinics, Walgreens), and direct-to-consumer home environments. Both private payers and government bodies (such as CMS in the U.S.) are increasingly incentivizing decentralized diagnostic pathways that lower total overhead costs and shorten emergency room stay times.
Market Challenges
• Strict regulatory hurdles, quality control, and CLIA waiver limitations: While the market for consumer-grade self-testing is expanding, obtaining regulatory approvals for high-complexity or novel molecular POC devices remains a arduous process. In the U.S., for a POC diagnostic device to be operated by non-laboratory personnel in non-traditional settings, it must secure a CLIA (Clinical Laboratory Improvement Amendments) Waiver from the FDA. Achieving this status requires manufacturers to prove that the device is nearly foolproof, highly accurate, and simple to operate without specialized training.• Reimbursement bottlenecks and high cost of advanced POC consumables: The initial capital investment for advanced automated POC analyzers, alongside the high per-test cost of microfluidic and molecular disposable cartridges, presents a financial obstacle for small clinics and physician practices. Unlike central lab automated platforms that benefit from massive scale and negligible per-sample reagent costs, single-use POC cartridges carry relatively high production costs. Compounding this issue are uneven reimbursement structures; public and private health insurers in North America often reimburse POC testing at rates lower than traditional central lab diagnostics, or impose strict pre-authorization criteria.
Market Trends
• Transition to digitalization, connectivity, and AI-driven diagnostic integration: Modern POC diagnostics in North America are no longer isolated, standalone instruments; they are evolving into fully connected digital nodes within healthcare IT ecosystems. Leading manufacturers are embedding Bluetooth, Wi-Fi, and cloud connectivity into portable diagnostic devices, allowing test results to automatically sync in real-time with Electronic Health Record (EHR) platforms (e.g., Epic, Cerner). Furthermore, artificial intelligence (AI) and machine learning algorithms are being integrated into diagnostic software to interpret subtle biomarker variations, reduce user interpretation errors, and provide predictive clinical decision support to primary care providers.• Miniaturization and advancement in lab-on-a-chip and isothermal molecular technologies: Technologically, the North American market is rapidly shifting from conventional lateral-flow immunoassay strips to microfluidic Lab-on-a-Chip (LOC) platforms and isothermal nucleic acid amplification (molecular) technologies. Microfluidics enables precise manipulation of micro-liter sample volumes (such as a single finger-prick of blood or a nasal swab), integrating sample preparation, fluid mixing, and multi-analyte reaction processing onto a single disposable plastic cartridge. Combined with isothermal amplification techniques (which bypass the bulky thermal cycling equipment required for standard PCR), manufacturers can now offer benchtop and hand-held devices that deliver central-lab-grade molecular accuracy within 10 to 20 minutes.
Point of Care Diagnostics Segmentation
| By Product | Glucose Monitoring Kits | |
| Infectious Diseases Testing Kits | ||
| Pregnancy And Fertility Testing Kits | ||
| Hematology Testing Kits | ||
| Cardiometabolic Monitoring Kits | ||
| Urinalysis Testing Kits | ||
| Cholesterol Test Strips | ||
| Other Products | ||
| By Technology/Platform | Lateral Flow Assays | |
| Molecular Diagnostics (PCR/INAAT) | ||
| Microfluidics & Immunoassays | ||
| Dipsticks & Test Strips | ||
| By End-User | Hospitals & Critical Care Centers | |
| Clinical & Diagnostic Laboratories | ||
| Home Care & Self-Testing | ||
| North America | United States | |
| Canada | ||
| Mexico | ||
High frequency of diabetes management and the need for repeated, immediate glucose checks make glucose monitoring kits a major point-of-care product category in North America. Glucose monitoring kits have a strong foundation in routine diabetes management because blood glucose measurement is not a one-time diagnostic activity but a repeated part of day-to-day disease management. The U.S. Centers for Disease Control and Prevention states that monitoring blood sugar is an important component of diabetes management because food, medicines, physical activity, illness, and other factors can change glucose levels during the day. The FDA explains that blood glucose monitoring systems consist of a meter and test strips that measure glucose from a small blood sample and can be used both in homes and healthcare settings. This combination of a portable instrument and disposable consumables supports repeated testing rather than occasional laboratory use. FDA guidance also specifically distinguishes over-the-counter self-monitoring systems for lay users from prescription point-of-care systems used in hospitals, physician offices, and long-term-care facilities, demonstrating that glucose testing is established across both consumer and professional environments. In addition, the CDC notes that glucose results obtained through waived testing can influence diabetes treatment decisions, including medication management. Consequently, glucose monitoring kits benefit from a combination of chronic disease prevalence, frequent testing requirements, established home-use practices, clinical acceptance, and the availability of simple finger-stick systems. Unlike many point-of-care tests that are performed only when a patient develops a particular symptom or enters a healthcare facility, glucose monitoring can occur repeatedly at home, in clinics, hospitals, and other care environments, giving this product category a particularly broad range of practical applications. Dipsticks and test strips lead the point-of-care technology/platform category because they provide simple, rapid, low-complexity testing across numerous analytes without requiring sophisticated laboratory infrastructure. Dipsticks and test strips are particularly well suited to point-of-care environments because the testing process can be performed close to the patient with limited equipment, small specimen requirements, and relatively straightforward operating procedures. A review published in PubMed describes urine dipsticks as dry-chemistry tools that are useful in point-of-care settings because of their practical and low-cost characteristics, while also noting that their results have limitations and should be interpreted within the appropriate clinical context. Their broad analytical utility is another important factor: reagent strips can assess parameters such as glucose, protein, blood, pH, specific gravity, ketones, bilirubin, leukocytes, nitrites, and urobilinogen, allowing one strip format to address several routine clinical questions. FDA CLIA records demonstrate that numerous urine dipstick systems are classified as waived tests, including products covering leukocytes and nitrites for urinary tract infection testing and strips measuring several urinalysis parameters. The FDA database also contains recent 2026 examples of waived urinalysis reagent strips covering multiple analytes, illustrating that this testing format remains actively used and regulated in the U.S. The CDC explains that waived tests are designed to be simple and low-risk and that sites performing only waived tests generally have fewer regulatory requirements than facilities performing moderate- or high-complexity testing, although proper procedures remain essential. This operational simplicity makes strips practical for physician offices, clinics, pharmacies, urgent-care environments, community settings, and some home-testing applications. Another advantage is that the result is available close to the time of specimen collection, reducing dependence on specimen transport to a central laboratory for basic screening decisions. Point-of-care literature also identifies visually interpreted dipsticks and kits as simple POCT formats that can use unprocessed urine or whole blood. Hospitals and critical care centers are the largest end-user segment because they require rapid diagnostic information repeatedly to support time-sensitive decisions for acutely ill and closely monitored patients. Hospitals and critical care centers have a fundamental operational need for point-of-care testing because many patients experience rapidly changing physiological conditions in which waiting for conventional laboratory turnaround can complicate immediate clinical decision-making. Point-of-care testing is specifically defined by the CDC as testing performed at or near the location of patient care, including settings such as the bedside, and its value becomes particularly evident when clinicians need information while treatment is actively underway. Blood gas testing provides a clear example: medical literature identifies blood gas analysis as a frequently performed point-of-care test in intensive care units, emergency departments, and operating rooms because it provides information about acid-base balance, ventilation, oxygenation, and metabolic status. Critical-care patients may require repeated measurements rather than a single test, making rapid access to results particularly important. A review of point-of-care blood gases, electrolytes, and lactate testing describes shorter therapeutic turnaround time, faster clinical decision-making, rapid data availability, small sample requirements, and the ability to perform serial whole-blood testing as important advantages in emergency and critical-care environments. Hospitals also provide multiple departments where point-of-care testing can be integrated, including emergency departments, intensive-care units, operating rooms, cardiac-care areas, and other acute-care locations. OTC products have a strong position in point-of-care diagnostics because they allow consumers to perform selected tests without first obtaining a prescription or relying entirely on a clinical laboratory visit. Over-the-counter point-of-care products are supported by the practical shift of certain basic diagnostic activities into the home and other consumer-accessible environments. The FDA specifically recognizes self-monitoring blood glucose test systems intended for over-the-counter home use by lay users and maintains separate regulatory guidance for these products compared with prescription point-of-care glucose systems used by professional healthcare providers. This distinction is important because it demonstrates that consumer-directed diagnostic testing is an established regulatory category rather than simply an informal extension of clinical laboratory testing. The FDA also explains that blood glucose meters can be used in both home and healthcare settings and that the systems generally combine a handheld meter with test strips for analyzing a small blood sample. Home testing is particularly relevant for conditions where measurements need to be repeated over time. The CDC states that regular blood sugar monitoring helps people with diabetes understand how food, medicines, and physical activity affect their glucose levels and can provide information that supports discussions with healthcare professionals about diabetes care. OTC testing also benefits from the availability of simple formats such as test strips, dipsticks, meters, and other self-contained kits that do not necessarily require specialized laboratory equipment. The FDA's database contains numerous glucose monitoring systems cleared for home use, illustrating the long-established presence of consumer-oriented glucose testing products in the U.S. Beyond glucose, FDA CLIA records show that urinary tract infection test strips and other urinalysis products have also received waived classifications, including systems for leukocytes and nitrites. These regulatory pathways support consumer access to selected diagnostic tests while still imposing requirements concerning performance, labeling, and appropriate use. OTC products therefore benefit from convenience, home accessibility, repeated self-monitoring, reduced dependence on appointments for certain basic measurements, and established consumer familiarity with rapid diagnostic formats. Blood is the leading sample type because many clinically important point-of-care measurements can be obtained rapidly from small blood specimens and directly reflect physiological conditions requiring immediate assessment. Blood is highly suitable for point-of-care diagnostics because it provides access to a wide range of measurable physiological and biochemical parameters from a relatively small specimen. A major advantage is the ability to obtain capillary blood through a finger stick for tests such as glucose monitoring, while venous or arterial blood can be used for more complex measurements depending on the clinical application. The FDA describes blood glucose monitoring systems as devices that measure glucose using a small sample of blood, illustrating how a minimal specimen can support repeated testing outside a conventional laboratory. Blood also plays a central role in emergency and critical-care testing. Medical literature describes point-of-care blood gas testing as important for evaluating acid-base balance, ventilation, oxygenation, electrolytes, and metabolic conditions in critically ill patients, with arterial blood commonly used for blood gas analysis and venous blood used for many general laboratory tests. Another practical advantage is speed. Point-of-care blood testing can reduce the time between specimen collection and availability of clinically relevant information, which is especially important when patients require rapid intervention. Reviews of blood gas and electrolyte testing identify rapid data availability, reduced therapeutic turnaround time, small sample volumes, and the ability to conduct frequent serial whole-blood testing as important characteristics of point-of-care systems. Blood samples also support multiple diagnostic areas, including glucose, blood gases, electrolytes, lactate, hemoglobin, coagulation-related measurements, infectious-disease testing, cardiac biomarkers, and other biochemical or hematological parameters depending on the device. The sample is therefore versatile rather than restricted to one diagnostic application. In addition, point-of-care systems can be designed around capillary, venous, or arterial collection, allowing the specimen type to be matched to the patient's condition and the test being performed. Literature on POCT notes that whole blood and capillary finger-stick samples can facilitate testing where conventional phlebotomy is not readily available.
to Download this information in a PDF
Point of Care Diagnostics Market Regional Insights
The United States represents the largest regional component because it combines a very large healthcare delivery infrastructure with extensive use of regulated point-of-care testing across hospitals, clinics, physician offices, pharmacies, and home settings. The United States has several structural characteristics that support extensive use of point-of-care diagnostics within North America. One is the scale and diversity of its healthcare delivery system, which includes hospitals, outpatient clinics, physician offices, long-term-care facilities, emergency departments, pharmacies, and home-based care. The American Hospital Association reports 6,100 hospitals in its 2026 Fast Facts, including 5,121 community hospitals and 907,216 staffed hospital beds based on its 2024 annual survey data. This broad institutional network creates numerous locations where rapid diagnostic tests can be performed close to patients. The U.S. also has a mature regulatory framework for point-of-care testing through the Clinical Laboratory Improvement Amendments, with the CDC explaining that facilities performing testing on human specimens for health assessment are subject to CLIA requirements and that waived tests include systems cleared by the FDA for home use as well as tests granted a CLIA waiver. The United States also has a substantial chronic-disease burden that supports recurring use of certain point-of-care tests. The CDC estimated that 40.1 million Americans had diagnosed or undiagnosed diabetes in 2023, while 115.2 million U.S. adults had prediabetes, demonstrating a large population in which glucose-related testing can play a role in disease detection or management. The U.S. regulatory environment additionally supports both professional and consumer testing pathways. FDA guidance separately addresses over-the-counter self-monitoring blood glucose systems and prescription point-of-care systems used in hospitals, physician offices, and long-term-care facilities. The FDA's databases also document numerous home-use glucose monitoring devices and a broad range of waived urinalysis and rapid-testing systems. These facts indicate that point-of-care diagnostics in the United States are embedded across multiple levels of healthcare rather than being concentrated in a single setting.
to Download this information in a PDF
Companies Mentioned
- Abbott Laboratories
- Danaher
- F. Hoffmann-La Roche AG,
- Siemens Healthineers
- OraSure Technologies
- Thermo Fisher Scientific Inc
- QIAGEN N.V.
- QuidelOrtho Corporation
- Becton, Dickinson and Company
- bioMérieux
- EKF Diagnostics
- Werfen S.A.
Table of Contents
- 1. Executive Summary
- 2. Market Dynamics
- 2.1. Market Drivers & Opportunities
- 2.2. Market Restraints & Challenges
- 2.3. Market Trends
- 2.4. Supply chain Analysis
- 2.5. Policy & Regulatory Framework
- 2.6. Industry Experts Views
- 3. Research Methodology
- 3.1. Secondary Research
- 3.2. Primary Data Collection
- 3.3. Market Formation & Validation
- 3.4. Report Writing, Quality Check & Delivery
- 4. Market Structure
- 4.1. Market Considerate
- 4.2. Assumptions
- 4.3. Limitations
- 4.4. Abbreviations
- 4.5. Sources
- 4.6. Definitions
- 5. Economic /Demographic Snapshot
- 6. North America Point of Care Diagnostics Market Outlook
- 6.1. Market Size By Value
- 6.2. Market Share By Country
- 6.3. Market Size and Forecast, By Product
- 6.4. Market Size and Forecast, By Technology/Platform
- 6.5. Market Size and Forecast, By End-User
- 6.6. Market Size and Forecast, By Mode Of Purchase
- 6.7. Market Size and Forecast, By Sample
- 6.8. United States Point of Care Diagnostics Market Outlook
- 6.8.1. Market Size by Value
- 6.8.2. Market Size and Forecast By Product
- 6.8.3. Market Size and Forecast By Technology/Platform
- 6.8.4. Market Size and Forecast By End-User
- 6.9. Canada Point of Care Diagnostics Market Outlook
- 6.9.1. Market Size by Value
- 6.9.2. Market Size and Forecast By Product
- 6.9.3. Market Size and Forecast By Technology/Platform
- 6.9.4. Market Size and Forecast By End-User
- 6.10. Mexico Point of Care Diagnostics Market Outlook
- 6.10.1. Market Size by Value
- 6.10.2. Market Size and Forecast By Product
- 6.10.3. Market Size and Forecast By Technology/Platform
- 6.10.4. Market Size and Forecast By End-User
- 7. Competitive Landscape
- 7.1. Competitive Dashboard
- 7.2. Business Strategies Adopted by Key Players
- 7.3. Porter's Five Forces
- 7.4. Company Profile
- 7.4.1. Abbott
- 7.4.1.1. Company Snapshot
- 7.4.1.2. Company Overview
- 7.4.1.3. Financial Highlights
- 7.4.1.4. Geographic Insights
- 7.4.1.5. Business Segment & Performance
- 7.4.1.6. Product Portfolio
- 7.4.1.7. Key Executives
- 7.4.1.8. Strategic Moves & Developments
- 7.4.2. F. Hoffmann-La Roche Ltd.
- 7.4.3. Siemens Healthineers AG
- 7.4.4. QuidelOrtho Corporation
- 7.4.5. Danaher
- 7.4.6. Becton, Dickinson and Company
- 7.4.7. Thermo Fisher Scientific
- 7.4.8. bioMérieux
- 7.4.9. EKF Diagnostics
- 7.4.10. QIAGEN
- 7.4.11. Werfen S.A.
- 7.4.12. OraSure Technologies
- 8. Strategic Recommendations
- 9. Annexure
- 9.1. FAQ`s
- 9.2. Notes
- 10. Disclaimer
Table 2: Top 10 Counties Economic Snapshot 2024
Table 3: Economic Snapshot of Other Prominent Countries 2022
Table 4: Average Exchange Rates for Converting Foreign Currencies into U.S. Dollars
Table 5: North America Point of Care Diagnostics Market Size and Forecast, By Product (2020 to 2031F) (In USD Billion)
Table 6: North America Point of Care Diagnostics Market Size and Forecast, By Technology/Platform (2020 to 2031F) (In USD Billion)
Table 7: North America Point of Care Diagnostics Market Size and Forecast, By End-User (2020 to 2031F) (In USD Billion)
Table 8: North America Point of Care Diagnostics Market Size and Forecast, By Mode Of Purchase (2020 to 2031F) (In USD Billion)
Table 9: North America Point of Care Diagnostics Market Size and Forecast, By Sample (2020 to 2031F) (In USD Billion)
Table 10: United States Point of Care Diagnostics Market Size and Forecast By Product (2020 to 2031F) (In USD Billion)
Table 11: United States Point of Care Diagnostics Market Size and Forecast By Technology/Platform (2020 to 2031F) (In USD Billion)
Table 12: United States Point of Care Diagnostics Market Size and Forecast By End-User (2020 to 2031F) (In USD Billion)
Table 13: Canada Point of Care Diagnostics Market Size and Forecast By Product (2020 to 2031F) (In USD Billion)
Table 14: Canada Point of Care Diagnostics Market Size and Forecast By Technology/Platform (2020 to 2031F) (In USD Billion)
Table 15: Canada Point of Care Diagnostics Market Size and Forecast By End-User (2020 to 2031F) (In USD Billion)
Table 16: Mexico Point of Care Diagnostics Market Size and Forecast By Product (2020 to 2031F) (In USD Billion)
Table 17: Mexico Point of Care Diagnostics Market Size and Forecast By Technology/Platform (2020 to 2031F) (In USD Billion)
Table 18: Mexico Point of Care Diagnostics Market Size and Forecast By End-User (2020 to 2031F) (In USD Billion)
Table 19: Competitive Dashboard of top 5 players, 2025
Figure 2: North America Point of Care Diagnostics Market Share By Country (2025)
Figure 3: United States Point of Care Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 4: Canada Point of Care Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 5: Mexico Point of Care Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 6: Porter's Five Forces of Global Point of Care Diagnostics Market
Point of Care Diagnostics Market Research FAQs
Related Reports
One individual can access, store, display, or archive the report in Excel format but cannot print, copy, or share it. Use is confidential and internal only. License information
One individual can access, store, display, or archive the report in PDF format but cannot print, copy, or share it. Use is confidential and internal only. License information
Up to 10 employees in one region can store, display, duplicate, and archive the report for internal use. Use is confidential and printable. License information
All employees globally can access, print, copy, and cite data externally (with attribution to Bonafide Research). License information
Safe and Secure SSL Encrypted
Quick Contacts
Want to customize this report?
We offer 10% Free Customization at the time of purchase
Get Free Customization
Our Clients
Budget constraints? Get in touch with us for special pricing
Request DiscountOrder Detail
- Order Placed (23 September, 2026)
- Notify To Team (23 September, 2026)
- Report updation (24 September, 2026)
- Report Quality Check (24 September, 2026)
- Report Dispatch (25 September, 2026)
- Hard Copy
Recently Viewed Products
North America Point of Care Diagnostics Market Outlook, 2031
We are friendly and approachable, give us a call.